NEW YORK-- A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:. Molycorp Inc. rose 10.9 percent to $7.23. Herbalife Ltd. rose 9.2 percent to $48.55.
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Advanced Micro Devices Inc. rose 5.6 percent to $4.17 with 36,266,100 shares traded. Annaly Mortgage Management Inc. fell 3.1 percent to $14.59 with 13,332,300 shares traded.
NEW YORK-- A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:. Actavis Inc.: Approximately 8,003,900 shares changed hands, a 579.8 percent increase over its 65- day average volume. The shares rose $13.05 or 12.2 percent to $119.86.
NEW YORK, May 10- The S&P 500 and Nasdaq rose modestly on Friday and indexes were on track for a third week of gains as an earnings-driven rally in Priceline's stock helped offset a slide in energy shares.
*Indexes on track for third straight week of gains. NEW YORK, May 10- U.S. stocks traded mostly flat on Friday as a sharp drop in commodity prices hit energy and materials shares, though the S&P 500 drew support from Priceline's earnings-related gain.
NEW YORK-- A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:. Molycorp Inc. rose 24.2 percent to $6.94. Restoration Hardware Holdings Inc. rose 17.9 percent to $47.47.
NEW YORK-- A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. Advanced Micro Devices Inc. rose. 8 percent to $3.89 with 16,177,200 shares traded. Bank of America Corp. rose. 7 percent to $13.00 with 52,483,400 shares traded.
Molycorp Inc.' s shares jumped Friday after the rare earth product company reported a better-than-expected first quarter that beat Wall Street forecasts. THE SPARK: Molycorp on Thursday posted a loss of $47.2 million, or 33 cents per share, for the quarter that ended March 31.
*Nasdaq rises after results from Priceline, Nvidia. "We're getting more constructive on the second half of the year as both the market and the economy are picking up," said Terry DuFrene, investment specialist for JP Morgan Private Bank in New Orleans. "
*Boeing may be able to boost Q4 deliveries of 787 s. NEW YORK, May 10- U.S. stock index futures pointed to a flat open on Friday, though indexes remained on track for a firm finish to the week, which repeatedly saw the indexes scaling new highs.
*Boeing may be able to boost Q4 deliveries of 787 s. NEW YORK, May 10- U.S. stock index futures edged higher on Friday as the market's recent momentum returned, putting equities on track for a strong week that repeatedly took indexes to record highs.
May 9- U.S. rare earths producer Molycorp Inc said on Thursday that it had a wider loss in the first quarter after higher costs and weak rare earth prices, which it said had declined more in recent weeks. Molycorp is nearing completion of a $1.25 billion modernization and expansion at its main mine, Mountain Pass, in California.
*Power-one and Microchip enter into patent license agreement. *Power-one- entered into non-exclusive field of use agreement with Microchip. Technology for digital power technology patents from Power One-.
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
**RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.
**RADCOM LTD, $4.05, up 53 pct. **LINKEDIN CORP, $181.69, down 10 pct. The U.S. Justice Department is suing the company and its hospice subsidiaries, including the biggest U.S. for-profit hospice chain, alleging false billings for Medicare hospice services.
May 3- Microchip Technology Inc:. *Needham raises price target to $43 from $40; rating buy.
**LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.